TECNOLOGÍA PARA LA MONITORIZACIÓN Y CONTROL DE LA DIABETES

Volver

Resultados 115 resultados LastUpdate Última actualización 21/01/2019 [17:26:00] pdf PDF




Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 5 nextPage   Mostrar por página


ANALYTE SENSOR DATA EVALUATION AND ERROR REDUCTION APPARATUS AND METHODS

NºPublicación: WO2019013936A1 17/01/2019

Solicitante:
GLYSENS INCORPORATED [US]

Resumen de: WO2019013936A1

Apparatus and methods for error modeling and correction in a blood analyte sensor or system. In one exemplary embodiment, the apparatus employs: (i) a training mode of operation, whereby the apparatus conducts "machine learning" to model one or more errors (e.g., unmodeled variable system errors) associated with the blood analyte measurement process, and (ii) generation of an operational model (based at least in part on data collected/received in the training mode), which is applied to correct or compensate for the errors during normal operation and collection of blood analyte data. This enhances device signal stability and accuracy over extended periods, thereby enabling among other things extended periods of blood analyte sensor implantation, and "personalization" of the sensor apparatus to each user receiving an implant. In one variant, the blood analyte is glucose, and the implanted sensor utilizes an oxygen-based molecular measurement principle.



traducir


 

Subcutaneous Outpatient Management

NºPublicación: US2019019577A1 17/01/2019

Solicitante:
ASEKO INC [US]

Resumen de: US2019019577A1

A method of administering insulin includes receiving subcutaneous information for a patient at a computing device and executing a subcutaneous outpatient program for determining recommended insulin dosages. The subcutaneous outpatient program includes obtaining blood glucose data of the patient from a glucometer in communication with the computing device, aggregating blood glucose measurements to determine a representative aggregate blood glucose measurement associated with at least one scheduled blood glucose time interval, and determining a next recommended insulin dosage for the patient based on the representative aggregate blood glucose measurement and the subcutaneous information. The method also includes transmitting the next recommended insulin dosage to a portable device associated with the patient. The portable device displays the next recommended insulin dosage.



traducir


 

MULTI-SCALE DISPLAY OF BLOOD GLUCOSE INFORMATION

NºPublicación: US2019015025A1 17/01/2019

Solicitante:
BIGFOOT BIOMEDICAL INC [US]

Resumen de: US2019015025A1

A method of displaying blood glucose information may include monitoring blood glucose levels of a user, where the blood glucose levels include at least a current blood glucose level and a historic blood glucose level. The method may also include presenting the current blood glucose level using a point indicator along an approximately horizontally centered axis based on a non-linear scale, and presenting the historic blood glucose level and a predicted future blood glucose level on the display as a single smoothed curve passing the point indicator.



traducir


 

MULTI-SCALE DISPLAY OF BLOOD GLUCOSE INFORMATION

NºPublicación: US2019015024A1 17/01/2019

Solicitante:
BIGFOOT BIOMEDICAL INC [US]

Resumen de: US2019015024A1

A system for displaying blood glucose information includes a blood glucose monitoring device configured to monitor blood glucose levels of a user, and a display. The system may also include one or more processors, and a non-transitory computer-readable medium containing instructions that, when executed by the one or more processors, cause the system to perform operations. The operations may include obtaining the blood glucose levels from the blood glucose monitoring device, where the blood glucose levels include at least a current blood glucose level and a historic blood glucose level. The operations may also include presenting the current blood glucose level at a first location on the display based on a first scale, and presenting the historic blood glucose level at a second location on the display based on a second scale different from the first scale.



traducir


 

Means and Method for Improved Glycemic Control for Diabetic Patients

NºPublicación: US2019019572A1 17/01/2019

Solicitante:
ASEKO INC [US]

Resumen de: US2019019572A1

A glycemic control system includes a physician processor, remote processor, and a portable telephone having a data input mechanism, a display, and an internal processor for bi-directional communication with the physician's processor and the remote processor. A patient inputs data to the internal processor responsive to input from the physician's processor and then transmits the information to the remote processor where an optimized number of units to be administered is sent back and displayed on the portable telephone.



traducir


 

CONTACT LENS FOR DETECTING GLUCOSE LEVEL IN TEARS AND METHOD FOR MAKING THE SAME

NºPublicación: US2019015022A1 17/01/2019

Solicitante:
HON HAI PREC IND CO LTD [TW]

Resumen de: US2019015022A1

A contact lens for detecting body glucose in tears includes a gel substrate, a plurality of platinum nanoparticles dispersed in the gel substrate, and a biosensor received in the gel substrate. The biosensor receives the glucose from tears as glucose oxidase and the glucose acid and hydrogen peroxide (H2O2) produced are decomposed to water and hydrogen peroxide. The platinum nanoparticles function as a catalytic agent to accelerate the degradation of the hydrogen peroxide into water and oxygen, avoiding or reducing hypoxia of the eye.



traducir


 

PRESENTATION METHOD, PRESENTATION DEVICE, AND COMPUTER READABLE MEDIUM

NºPublicación: US2019015054A1 17/01/2019

Solicitante:
ARKRAY INC [JP]

Resumen de: US2019015054A1

A presentation method for presenting a time period to measure a blood glucose level, the presentation method includes: acquiring first information, the first information including a measurement result in which a glucose level of a user is measured with a time interval using a first measurement device and a measurement time at which the measurement result was acquired; determining, based on a comparison result obtained by comparing the first information with a predetermined threshold of the glucose level and a preset period, the time period for the user to measure the blood glucose level by using a second measurement device; and presenting the time period at a display.



traducir


 

METHOD AND SYSTEM FOR NON-INVASIVE OPTICAL BLOOD GLUCOSE DETECTION UTILIZING SPECTRAL DATA ANALYSIS

NºPublicación: US2019015027A1 17/01/2019

Solicitante:
ST LOUIS MEDICAL DEVICES INC [US]

Resumen de: US2019015027A1

Systems and methods are disclosed for non-invasively measuring blood glucose levels in a biological sample based on spectral data. This includes utilizing at least one light source configured to strike a target area of a sample, utilizing at least one light filter positioned to receive light transmitted through the target area of the sample from the at least one light source, utilizing at least one light detector positioned to receive light from the at least one light source and filtered by the at least one light filter, and to generate an output signal, having a time dependent current, which is indicative of the power of light detected, receiving the output signal from the at least one light detector with a processor, calculating the attenuance attributable to blood with a ratio factor based on the received output signal, and determining a blood glucose level based on the calculated attenuance.



traducir


 

TRANSCUTANEOUS ANALYTE SENSOR

NºPublicación: US2019015020A1 17/01/2019

Solicitante:
DEXCOM INC [US]

Resumen de: US2019015020A1

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.



traducir


 

METHOD AND SYSTEM FOR NON-INVASIVE OPTICAL BLOOD GLUCOSE DETECTION UTILIZING SPECTRAL DATA ANALYSIS

NºPublicación: US2019015026A1 17/01/2019

Solicitante:
ST LOUIS MEDICAL DEVICES INC [US]

Resumen de: US2019015026A1

Systems and methods are disclosed for non-invasively measuring blood glucose levels in a biological sample based on spectral data. This includes utilizing at least one light source configured to strike a target area of a sample, utilizing at least one light filter positioned to receive light transmitted through the target area from the at least one light source, utilizing at least one light detector positioned to receive light from the at least one light source and filtered by the at least one light filter, and to generate an output signal, having a time dependent current, which is indicative of the power of light detected, receiving the output signal from the at least one light detector with a processor and based on the received output signal, calculating the attenuance attributable to blood in a sample with a signal-to-noise ratio of at least 20-to-1; and determining a blood glucose level.



traducir


 

FLUID DELIVERY SYSTEM

NºPublicación: US2019015580A1 17/01/2019

Solicitante:
VICENTRA B V [NL]

Resumen de: US2019015580A1

A fluid delivery system (1) includes a reservoir (7) for storing a fluid, a pumping chamber (8) and an actuator (20). The pumping chamber (8) has a volume, an inlet valve (48) providing selective fluid communication between the pumping chamber volume and the reservoir, an outlet valve (49), and a membrane (47) the displacement of which changes the pumping chamber volume. The actuator (20) moves a drive member (21) in reciprocating motion. The actuator (20) is disposed in a housing (9) having an aperture (36) from which the drive member projects. The reservoir (7) and the pumping chamber (8) are arranged in a cartridge (3) removably attachable to the housing. When the cartridge (3) is attached to the housing (9) the drive member (20) is operatively coupled to the pumping chamber membrane (47). The fluid delivery system may be applied to an infusion system for the infusion of a liquid therapeutic product, such as insulin.



traducir


 

METHODS FOR TREATING CONGENITAL HYPERINSULINISM

NºPublicación: WO2019014658A1 17/01/2019

Solicitante:
XERIS PHARMACEUTICALS INC [US]

Resumen de: WO2019014658A1

A method of treating congenital hyperinsulinism in a subject is disclosed. The method can include parenterally administering to the subject a first composition comprising a glucagon, a glucagon analogue, or a salt form of either thereof, and optionally administering to the subject a second composition comprising glucose, a glucose analogue, or a salt form of either thereof, wherein administration of the first composition sufficiently increases blood glucose level in the subject such that the second composition is not administered or the second composition is administered at a glucose infusion rate (GIR) of less than 8 mg/(kg*min).



traducir


 

MULTI-SCALE DISPLAY OF BLOOD GLUCOSE INFORMATION

NºPublicación: WO2019014594A1 17/01/2019

Solicitante:
DESBOROUGH LANE [US]
MAZLISH BRYAN [US]
KABEL ECKES SABINE [US]
BOISSIER JEFF [US]

Resumen de: WO2019014594A1

A method of displaying blood glucose information may include monitoring blood glucose levels of a user, where the blood glucose levels include at least a current blood glucose level and a historic blood glucose level. The method may also include presenting the current blood glucose level using a point indicator along an approximately horizontally centered axis based on a non-linear scale, and presenting the historic blood glucose level and a predicted future blood glucose level on the display as a single smoothed curve passing the point indicator.



traducir


 

MULTI-SCALE DISPLAY OF BLOOD GLUCOSE INFORMATION

NºPublicación: WO2019014590A1 17/01/2019

Solicitante:
DESBOROUGH LANE [US]
MAZLISH BRYAN [US]
KABEL ECKES SABINE [US]
BOISSIER JEFF [US]

Resumen de: WO2019014590A1

A system for displaying blood glucose information includes a blood glucose monitoring device configured to monitor blood glucose levels of a user, and a display. The system may also include one or more processors, and a non-transitory computer-readable medium containing instructions that, when executed by the one or more processors, cause the system to perform operations. The operations may include obtaining the blood glucose levels from the blood glucose monitoring device, where the blood glucose levels include at least a current blood glucose level and a historic blood glucose level. The operations may also include presenting the current blood glucose level at a first location on the display based on a first scale, and presenting the historic blood glucose level at a second location on the display based on a second scale different from the first scale.



traducir


 

A DEVICE FOR TEST PREPARATION OF BLOOD FOR DETERMINATION OF GLUCOSE CONCENTRATION IN BLOOD PLASMA

NºPublicación: EP3427833A1 16/01/2019

Solicitante:
LIND VICTOR [EE]
FEDOTOV MAXIM [EE]

Resumen de: EP3427833A1

The device for blood sample preparation for determining the concentration of glucose in the blood plasma relates to medicine, more specifically to clinical laboratory diagnostics and endocrinology, and can be used for the diagnosing of diabetes mellitus. The device is a vacuum vial with a bar code and a protective cover of grey colour assembled with a rubber stopper comprising an inert separation gel in an amount of 0.6-1.2 g at the bottom and a mixture of potassium oxalate with sodium fluoride on the walls of the vial. The device provides increased accuracy of determining the glucose concentration in blood plasma, reduces the time of sample preparation, reduces the risk of haemolysis during transportation and storage of blood, and reduces the risk of infection of laboratory personnel with blood-borne infections.



traducir


 

STABILIZED FORMULATIONS CONTAINING ANTI-NGF ANTIBODIES

NºPublicación: EP3427752A1 16/01/2019

Solicitante:
REGENERON PHARMA [US]

Resumen de: EP3427752A1

The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human nerve growth factor (hNGF). The formulations may contain, in addition to an anti-hNGF antibody, at least one non-ionic surfactant, at least one sugar, and acetate. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months



traducir


 

METHOD AND ELECTRONICS UNIT FOR DETECTING IN-VIVO PROPERTIES OF A BIOSENSOR

NºPublicación: WO2019007842A1 10/01/2019

Solicitante:
ROCHE DIABETES CARE GMBH [DE]
HOFFMANN LA ROCHE [CH]
ROCHE DIABETES CARE INC [US]

Resumen de: WO2019007842A1

A method for detecting in-vivo properties of a biosensor (110) is disclosed. Herein the biosensor (110) is, in interoperation with an electronics unit (202), adapted for electrochemically determining at least one value of an analyte (136) in a sample of a body fluid (140), wherein the biosensor (110) comprises at least one working electrode (120), wherein the working electrode (120) is covered by a membrane (132) and includes an enzyme (134) for providing a reaction with the analyte (136), wherein the membrane (132) has an electrical resistance and the working electrode (120) has an electrical capacitance. Further, the electronics unit (202) is adapted for measuring a raw current and a current response indicative of an admittance of the biosensor (110). Herein, the method comprises the steps of: a)providing a sensitivity-to-admittance relation of the biosensor (110); b) measuring a raw current in the biosensor (110); c) measuring an in-vivo current response indicative of the in-vivo admittance of the biosensor (110), wherein the in-vivo current response is measured at at least one first operating point (156) and at at least one second operating point (158), wherein the first operating point (156) is selected for providing a first characteristic value being related to the electrical resistance of the membrane (132), and wherein the second operating point (158) is selected for providing a second characteristic value being related to the electrical capacitance of the working ele



traducir


 

STABILIZED FORMULATIONS CONTAINING ANTI-NGF ANTIBODIES

NºPublicación: US2019010222A1 10/01/2019

Solicitante:
REGENERON PHARMA [US]

Resumen de: US2019010222A1

The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human nerve growth factor (hNGF). The formulations may contain, in addition to an anti-hNGF antibody, at least one non-ionic surfactant, at least one sugar, and acetate. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.



traducir


 

METHOD, DEVICE AND COMPUTER PROGRAM FOR MANAGING BLOOD SUGAR IN DIABETIC PATIENT BY USING TERMINAL DEVICE

NºPublicación: WO2019009610A1 10/01/2019

Solicitante:
SAMSUNG LIFE PUBLIC WELFARE FOUNDATION [KR]

Resumen de: WO2019009610A1

Disclosed in one embodiment of the present invention is a blood sugar control device using a patient terminal, comprising: a blood sugar measurement unit for acquiring the blood sugar level of a patient from a blood sugar measurement instrument connected to a terminal device; a feedback management unit for selecting, on the basis of the blood sugar level, a feedback massage to be provided to the patient, and reflecting the blood sugar level in the blood sugar control information stored in the memory of the terminal device; a display control unit for displaying the selected feedback message on the display part of the terminal device; and a communication unit for transmitting at least a part of the blood sugar control information to a management server, wherein the feedback management unit comprises: a condition setting unit for setting a first condition to be considered in the selection of the feedback message; and a feedback generation unit for selecting the feedback message.



traducir


 

METAL PILLAR DEVICE STRUCTURES AND METHODS FOR MAKING AND USING THEM IN ELECTROCHEMICAL AND/OR ELECTROCATALYTIC APPLICATIONS

NºPublicación: US2019008425A1 10/01/2019

Solicitante:
MEDTRONIC MINIMED INC [US]

Resumen de: US2019008425A1

The invention disclosed herein includes electrode compositions formed from processes that sputter metal in a manner that produces pillar architectures. Embodiments of the invention can be used in analyte sensors having such electrode architectures as well as methods for making and using these sensor electrodes. A number of working embodiments of the invention are shown to be useful in amperometric glucose sensors worn by diabetic individuals. However, the metal pillar structures have wide ranging applicability and should increase surface area and decrease charge density for catalyst layers or electrodes used with sensing, power generation, recording, and stimulation, in vitro and/or in the body, or outside the body.



traducir


 

DIABETES MANAGEMENT SYSTEM WITH ALERT STATUS INTERFACE AND PATIENT PRIORITIZATION

NºPublicación: US2019013091A1 10/01/2019

Solicitante:
ROCHE DIABETES CARE INC [US]

Resumen de: US2019013091A1

User interfaces are needed to alert and inform a person suffering from diabetes or a healthcare provider of possible harmful changes in the patient's blood glucose level. An improved method is presented for issuing an alert regarding a glucose condition of a patient by a diabetes management system. For a given patient, their glucose condition is quantified and presented as a state on a display. Glucose conditions can also be prioritized for a plurality of patients and presented to a healthcare provider.



traducir


 

BLOOD-GLUCOSE METER INTEGRATED WITH BIOLOGICAL TEST-PIECE TANK

NºPublicación: US2019011431A1 10/01/2019

Solicitante:
OK BIOTECH CO LTD [TW]

Resumen de: US2019011431A1

A blood-glucose meter integrated with a biological test-piece tank includes a biological test-piece tank and a blood-glucose meter. The biological test-piece tank has internally a chamber for providing an accommodation room to store a plurality of biological test pieces, a tank opening located at a top thereof to pair a cover so as to form a sealed structure, and a tank bottom located by opposing to the cover. The blood-glucose meter, connected with the tank bottom, has an inserting hole for receiving a biological test piece that carries thereon a biological specimen to be examined for obtaining a corresponding blood-glucose value.



traducir


 

ANALYTE SENSOR DATA EVALUATION AND ERROR REDUCTION APPARATUS AND METHODS

NºPublicación: US2019008461A1 10/01/2019

Solicitante:
GLYSENS INCORPORATED [US]

Resumen de: US2019008461A1

Apparatus and methods for error modeling and correction in a blood analyte sensor or system. In one exemplary embodiment, the apparatus employs: (i) a training mode of operation, whereby the apparatus conducts “machine learning” to model one or more errors (e.g., unmodeled variable system errors) associated with the blood analyte measurement process, and (ii) generation of an operational model (based at least in part on data collected/received in the training mode), which is applied to correct or compensate for the errors during normal operation and collection of blood analyte data. This enhances device signal stability and accuracy over extended periods, thereby enabling among other things extended periods of blood analyte sensor implantation, and “personalization” of the sensor apparatus to each user receiving an implant. In one variant, the blood analyte is glucose, and the implanted sensor utilizes an oxygen-based molecular measurement principle.



traducir


 

NEAR-IR GLUCOSE SENSORS

NºPublicación: US2019010170A1 10/01/2019

Solicitante:
PROFUSA INC [US]

Resumen de: US2019010170A1

Glucose-sensing luminescent dyes, polymers, and sensors are provided. Additionally, systems including the sensors and methods of using these sensors and systems are provided.



traducir


 

BOLUS CALCULATOR WITH PROBABILISTIC GLUCOSE MEASUREMENTS

Nº publicación: EP3423970A1 09/01/2019

Solicitante:
ROCHE DIABETES CARE GMBH [DE]

Resumen de: WO2017151372A1

Methods and devices involving using a bolus calculator for calculating a correction insulin dose accounting for continuous glucose monitoring noise. More specifically, methods and devices using an algorithm executed by a processor of the bolus calculator and using a glucose measurement and uncertainty of the glucose measurement to determine if a standard correction dose should be adjusted once calculations are performed for the standard correction dose and hypoglycemia-averse correction insulin dose and the two doses are compared.


traducir



 

Página1 de 5 nextPage Mostrar por página

Volver